Uncategorized

Building on our rich history of innovation, genome scientists, bioinformaticians and molecular pathologists at Memorial Sloan Kettering Cancer Center have developed a targeted tumor sequencing test, Integrated Mutation Profiling of Actionable Cancer Targets(MSK-IMPAC), to detect gene mutations and other critical genetic aberrations in both rare and common cancers. Until now, genomic testing of tumors has been routine practice only for patients with certain solid tumors, such as melanoma, lung, and colon cancer.

 

See origin article at: https://www.mskcc.org/msk-impact